Clicky

Insmed, Inc.(INSM)

Description: Insmed Incorporated, a biopharmaceutical company, focuses on developing and commercializing targeted inhalation therapies for patients battling serious lung diseases. Its lead candidate ARIKACE is engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the treatment for two identified patient populations comprising cystic fibrosis (CF) patients with Pseudomonas aeuruginosa lung infections and patients with nontuberculous mycobacteria lung infections (NTM). The company's Phase III registrational study of ARIKACE in CF patients in Europe and Canada has completed enrollment; and Phase II clinical trial in NTM patients is under way with clinical results. Insmed Incorporated was founded in 1999 and is headquartered in Monmouth Junction, New Jersey.


Keywords: Biopharmaceutical Infectious Diseases Microbiology Bacteriology Tuberculosis Cystic Fibrosis Bacterial Disease Pseudomonas Lung Diseases Lung Infection Mycobacterium Nontuberculous Mycobacteria Lung Infections

Home Page: www.insmed.com

INSM Technical Analysis

700 US Highway 202/206
Bridgewater, NJ 08807
United States
Phone: 908 977 9900


Officers

Name Title
Mr. William H. Lewis J.D., M.B.A. Pres, CEO & Chairman
Ms. Sara M. Bonstein MBA Chief Financial Officer
Mr. Roger Adsett Chief Operating Officer
Ms. S. Nicole Schaeffer Chief People Strategy Officer
Dr. Martina Flammer M.B.A., M.D. Chief Medical Officer
Mr. John Goll III Sr. VP & Chief Accounting Officer
Eleanor Barisser Associate Director of Investor Relations
Mr. Michael Alexander Smith Sr. VP & Gen. Counsel
Mandy Fahey Exec. Director of Corp. Communications
Mr. John Drayton Wise Sr. VP, Head of United States & Chief Commercial Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 48.1776
Price-to-Sales TTM: 10.886
IPO Date: 2000-06-01
Fiscal Year End: December
Full Time Employees: 613
Back to stocks